

- diagnosis of, 150e-2, 150e-2t, 150e-5t, 150e-6  
 inherited susceptibility to, 420t, 421, 422f  
 laryngitis, 234  
 leprosy. *See* Leprosy  
 nontuberculous. *See* Nontuberculous  
 mycobacterial infections  
 osteomyelitis, 836, 839, 844  
 subacute meningitis, 766t, 775, 898–899,  
 1111  
 tuberculosis. *See* Tuberculosis (TB)
- Mycobacterium intracellulare* infections. *See*  
*Mycobacterium avium* complex (MAC)  
 infections
- Mycobacterium kansasii* infections, 205e-8, 1130,  
 1131–1132
- Mycobacterium leprae*, 145e-4, 1123. *See also*  
 Leprosy
- Mycobacterium marinum*, 1106
- Mycobacterium marinum* infections  
 cellulitis, 830  
 skin, 366, 829, 1130  
 in transplant recipient, 926  
 treatment of, 205e-8, 830, 1132
- Mycobacterium orygis*, 1103
- Mycobacterium pinnipedii*, 1103
- Mycobacterium tuberculosis*. *See also*  
 Tuberculosis (TB)  
 adherence of, 145e-2t  
 host response to, 372e-26, 1106–1107  
 innate resistance to, 1106  
 microbiology of, 1102–1103, 1103f  
 phagosome of, 1105–1106  
 rifampin-resistant, 774, 778  
 transmission of, 1105  
 virulence of, 1106
- Mycobacterium ulcerans*, 829, 1130
- Mycophenolate mofetil/sodium  
 action of, 1829t  
 adverse effects of, 269, 1829t, 1831, 2071,  
 2130t  
 for bullous pemphigoid, 372  
 for drug-induced hypersensitivity syndrome,  
 382  
 drug interactions of, 2130t  
 for immunosuppression  
 after kidney transplantation, 1828, 1829t  
 after liver transplantation, 2071  
 for inflammatory myopathies, 2201  
 for interstitial lung diseases, 1711, 1712  
 for lupus nephritis, 1838  
 for mucous membrane pemphigoid, 374  
 for myasthenia gravis, 2705  
 for neuromyelitis optica, 2673  
 for pemphigus vulgaris, 371  
 for photoallergy, 390  
 for SLE, 2130t, 2132  
 for systemic sclerosis, 2164
- Mycoplasma* spp., 1163
- Mycoplasma genitalium* infections, 870–871,  
 872t, 876, 1164t, 1165
- Mycoplasma hominis* infections  
 in mediastinitis, 926  
 nonurogenital, 1165  
 postpartum/postabortal, 1165  
 in transplant recipient, 926  
 treatment of, 1164t, 1165  
 urogenital, 1165
- Mycoplasma* spp. infections  
 AGEP and, 382  
 in animal bite-wounds, 167e-1
- Mycoplasma pneumoniae*, 1163, 1164
- Mycoplasma pneumoniae* infections, **1163**  
 diagnosis of, 1164, 1164t  
 epidemiology of, 1163  
 extrapulmonary, 1163–1164  
 pathogenesis of, 1163  
 treatment of, 1164, 1164t  
 upper respiratory tract, 226, 231, 1163
- Mycosis fungoides (cutaneous T-cell lymphoma)  
 clinical features of, 501f, 707  
 peripheral blood smear in, 81e-10f  
 skin manifestations of, 76e-5f, 353, 353t, 354,  
 357t, 707  
 treatment of, 102e-5t, 103e-20, 391, 707
- Mycotic aneurysm  
 circle of Willis, 1784–1785. *See also*  
 Subarachnoid hemorrhage  
 clinical features of, 1639  
 etiology of, 1638  
 in infective endocarditis, 819, 826  
 treatment of, 1643
- Mycotoxins, hepatocellular carcinoma and, 544,  
 545t
- Myc transcription factor, 500
- MyD88, 86e-8, 145e-5, 145e-6f, 372e-5f
- MyD88 deficiency, 420t
- Mydriasis, 196
- Myelin  
 defects of, 444e-3f, 444e-5–6, 444e-5f  
 structure of, 444e-4, 444e-4f
- Myelin-associated glycoprotein (MAG),  
 372e-24t, 444e-8, 718
- Myelin basic protein (MBP), 372e-24t, 444e-4f
- Myelin gene regulatory factor (MRF), 444e-5
- Myelin oligodendrocyte glycoprotein (MOG),  
 372e-24t, 444e-4f
- Myelin protein zero (MPZ), 2678
- Myelitis. *See* Myelopathy, inflammatory and  
 immune
- Myeloblasts, 414f, 415
- Myelocytes, 414f, 415
- Myelodysplasia, 415, **669**  
 classification of, 669–670, 669t  
 clinical features of, 670  
 diagnosis of, 668f, 670–671  
 differential diagnosis of, 628  
 epidemiology of, 670  
 etiology of, 670  
 genetic considerations in, 670  
 hemoglobinopathy in, 639  
 pathophysiology of, 670  
 prognosis of, 671, 671t  
 as second malignancy in cancer survivors, 623  
 treatment of, 102e-8, 139e-6, 671
- Myelodysplastic syndromes (MDS). *See*  
 Myelodysplasia
- Myelofibrosis  
 primary. *See* Primary myelofibrosis  
 secondary, 671–672
- Myelography, 440e-2, 440e-9–10
- Myeloid dendritic cells, 372e-6, 372e-7t. *See also*  
 Dendritic cells
- Myeloid/erythroid ratio, 397
- Myeloid malignancies, **135e-4**  
 atypical chronic myeloid leukemia, 135e-5–6,  
 135e-5t  
 chronic myelomonocytic leukemia, 102e-3,  
 135e-5t, 135e-6, 669  
 chronic neutrophilic leukemia, 135e-5–6,  
 135e-6t, 672  
 classification of, 135e-4, 135e-4t  
 juvenile myelomonocytic leukemia (JMML),  
 135e-6  
 MDS/MPN, unclassifiable, 135e-6  
 MDS/MPN overlap, 135e-6  
 myelodysplastic syndromes. *See*  
 Myelodysplasia  
 myeloproliferative neoplasm, unclassifiable,  
 135e-6–7  
 transient myeloproliferative disorder (TMD),  
 135e-7
- Myeloid metaplasia. *See* Primary myelofibrosis
- Myeloma  
 multiple. *See* Multiple myeloma  
 sclerotic, 614, 618–619
- Myeloma kidney, 62e-7f, 1859, 1859f
- Myeloma light chains, 1804, 1805, 1859
- Myelopathy  
 chemotherapy-induced, 607t  
 chronic, **2657**  
 in adrenomyeloneuropathy, 2659  
 in cobalamin deficiency, 2659  
 familial spastic paraplegia. *See* Familial  
 spastic paraplegia (FSP)  
 HTLV-1 associated, 163, 225e-5, 697, 707,  
 2657–2658  
 hypocupric, 2659  
 in MS, 2659
- primary lateral sclerosis, 2636, 2659  
 spondylitic, 2657  
 in syringomyelia, 2658, 2658f  
 in tabes dorsalis, 1136, 2659  
 in tethered cord syndrome, 118, 2659  
 toxic, 2659  
 in vascular malformations of cord and dura,  
 2657, 2658f  
 compressive. *See* Spinal cord compression  
 compressive vs. noncompressive, 2653  
 evaluation of, 2655t  
 gait disorders in, 162t  
 in high-voltage electrical injury, 2657  
 in HIV infection, 1266–1267  
 inflammatory and immune (myelitis), **2656**  
 acute infectious, 441e-25f, 2656–2657  
 in multiple sclerosis, 2656. *See also* Multiple  
 sclerosis (MS)  
 in neuromyelitis optica, 2656, 2673  
 paraneoplastic, 616  
 postinfectious, 1212, 2656  
 in systemic immune-mediated disorders,  
 2656  
 noncompressive acute transverse, 2655, 2655t  
 paraneoplastic, 618, 2659  
 radiation-associated, 622  
 in spinal cord infarction, 441e-25f, 2656–2657
- Myeloperoxidase, 372e-24t, 416
- Myeloperoxidase deficiency, 419, 420t
- Myelophthisic anemias, 671–672
- Myeloproliferative disorders, **672**  
 classification of, 672, 672t  
 cutaneous ulcers in, 369  
 evolution into AML, 678  
 janus kinase inhibitors for, 102e-3  
 splenomegaly in, 411
- Myeloproliferative neoplasm, unclassifiable  
 (MPN-U), 135e-6–7
- Myelosuppression, chemotherapy-induced, 103e-  
 23–25, 103e-24t. *See also* Neutropenia
- Myenteric plexus, 264
- MYH7 gene mutations, 1555t, 1568
- MYH9 gene, 1241, 1241t
- MYH-associated polyposis, 538t, 539
- Myiasis, 2746–2747
- Myoadenylate deaminase deficiency, 431e-3t,  
 431e-6, 462e-15
- Myocardial contusion, 289e-3
- Myocardial fibrosis, radiation-associated, 621
- Myocardial infarction (MI)  
 abdominal pain in, 105, 106t  
 vs. acute pericarditis, 1571, 1575  
 arrhythmias in  
 AV conduction block, 1471t, 1472, 1609  
 SA node dysfunction, 1467, 1467t  
 sinus bradycardia, 1609  
 supraventricular, 1609  
 ventricular, 1496, 1608–1609, 1770  
 atherosclerosis and, 291e-4  
 cardiac arrest risk factors following, 1767,  
 1767f  
 cardiac imaging following, 270e-19–20,  
 270e-25f, 1464f  
 cardiogenic shock in. *See* Cardiogenic shock  
 chest pain in, 99f, 1594, 1599–1600,  
 1609–1610  
 circadian variations in, 194, 1599, 1616  
 classification of, 1602t  
 definition of, 1602t  
 dental care after, 242  
 diagnosis of  
 CMR, 271e-4f, 271e-4v  
 ECG, 269e-3–7f  
 echocardiography, 271e-1f, 271e-1v  
 history in, 99, 99f  
 myocardial perfusion imaging, 271e-5f  
 erectile dysfunction and, 328  
 hemodynamic patterns in, 1762t  
 in HIV infection, 1255  
 hypokalemia in, 64e-7, 305  
 hypothermia in, 478e-1  
 incidence of, 1593, 1594f, 1599  
 inflammatory mediators in, 372e-29t  
 in kidney transplant recipients, 1831